Posted inCardiology news
Rationale and Design of CARDIO-TTRansform: A Phase 3 Trial of Eplontersen for Transthyretin Amyloid Cardiomyopathy
CARDIO-TTRansform is a global Phase 3 trial evaluating eplontersen's efficacy and safety in reducing cardiovascular events in transthyretin amyloid cardiomyopathy patients receiving standard care, including TTR stabilizers. With 1,432 participants, it aims to establish a new treatment paradigm.